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Daratumumab (DARA), a drug used to treat patients with 
multiple myeloma, causes interference in pre-transfusion testing. 
Samples from patients receiving DARA exhibit panreactivity in 
antibody detection and identification tests with red blood cells 
(RBCs). Many hospitals are sending these samples to reference 
laboratories. Dithiothreitol (DTT), a sulfhydryl chemical treat-
ment of RBCs, negates this reactivity. This study investigated 
the stability of the antigens on DTT-treated RBCs to determine 
if large quantities of RBCs could be treated at one time, stored, 
and used for testing at a later time. Panel cells were treated with 
DTT and then stored as three sets. Set 1 DTT-treated RBCs were 
stored in Alsever’s solution at 2°C to 8°C, washed daily, and 
suspended in pH 7.3 phosphate-buffered saline (PBS) prior to 
antigen typing. Set 2 DTT-treated RBCs were stored in pH 7.3 
PBS. Set 3 DTT-treated RBCs were stored in Alsever’s solution. 
Sets 2 and 3 were inspected daily for 14 days for observation of 
hemolysis. In Set 1, all antigen reactivity remained at ≥2+ with 
both single- and double-dose cells for 14 days. The Rh antigens 
gave stronger reactions longer, compared with those tested in 
the Duffy, Kidd, and MNS blood group systems. Sets 2 and 3 
were monitored for hemolysis. On day 3, Set 2 began displaying 
hemolysis, with complete hemolysis by day 8. Set 3 did not display 
hemolysis in 14 days. In conclusion, a large volume of RBCs can be 
treated with DTT and stored in Alsever’s solution for use without 
deterioration of the RBC antigens, saving institutions tech 
time, resources, and money. Immunohematology 2017;33: 
105–109.
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Daratumumab (DARA) is a human monoclonal antibody 
shown to recognize CD38.1 DARA targets CD38, a glycoprotein 
found on the surface of many types of cells including B cells, 
which are overexpressed in patients with multiple myeloma.2 
This finding has been established as a successful treatment of 
patients with multiple myeloma and non-Hodgkin’s lymphoma. 
In clinical trials, DARA has been proven highly cytotoxic to 
tumor cells via complement-dependent cytotoxicity, antibody-
dependent cellular cytotoxicity, and apoptosis.1,3 The success and 
efficiency in treatment for this patient population has resulted in 
a marked increase of use and application across the field.
During routine blood bank testing, serum/plasma 
samples from patients on DARA exhibit panreactivity across 
varying methods of antibody detection and identification, 
preventing blood banks from providing crossmatch-
compatible red blood cell (RBC) units in a timely manner. 
With the increase in use of DARA, blood banks are sending 
increased numbers of these patient samples for antibody 
detection and identification to immunohematology reference 
laboratories (IRLs), causing delays in providing compatible 
RBC units and additional cost.
DARA binds with CD38 located on the reagent RBC 
membrane.2 Chapuy et al.2 reported that 0.2 M dithiothreitol 
(DTT) treatment of reagent RBCs can remove interference 
from DARA by disrupting the structure of the antigen. The 
DTT treatment then allows for the identification of underlying 
clinically significant antibodies. 
DTT treatment of reagent RBCs requires precise technical 
detail and is also very labor-intensive. Current practice is 
to DTT-treat a few drops of the reagent RBCs required for 
patient testing. This practice uses at least 40–60 minutes of 
technologist time every time a sample from a patient on DARA 
is encountered, in addition to the screening, identification, and 
crossmatch testing that may be required. Each batch of treated 
RBCs also requires the use of quality control to ensure that the 
denaturation process has been successful. It is recommended 
to obtain the patient’s RBC antigen phenotype or genotype 
prior to DARA use, but this testing is neither guaranteed nor 
accessible by all facilities.
Although the use of DTT-treated RBCs is recommended 
for testing current patients on DARA, the literature provides 
little information about the stability of the common RBC 
antigens when DTT-treated RBCs are stored. DTT-treated 
RBC panels are not commercially available. We investigated 
the stability of common clinically significant antigens on 
DTT-treated commercial panels by tube method with both 
commercial and human-source antisera. With these data, both 
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transfusion services and IRLs will have the necessary storage 
information for DTT-treated RBCs and their antigen stability.
Materials and Methods
DTT Preparation
One gram of DTT (Cleland’s Reagent; Sigma-Aldrich, 
St. Louis, MO) is dissolved in 32.4 mL phosphate-buffered 
saline (PBS; Sigma-Aldrich) with a pH of 7.3. The DTT-to-
PBS ratio may be adjusted depending on the desired volume 
of 0.2 M DTT.4
DTT Treatment
Two 11-cell panels (Panocell-10; Immucor, Norcross, GA) 
were DTT-treated. Each panel cell was placed into a labeled 
glass 12 × 75 mm test tube. Tubes were washed once with 
normal saline using a manual method. Four volumes of 0.2 M 
DTT were added to 1 volume of washed packed RBCs. The 
mixture was gently shaken, re-suspended, and incubated at 
37°C for 30–45 minutes in a dry heat block. After incubation, 
the DTT-treated RBCs were washed four times manually with 
normal saline.
After the last wash, the DTT-treated RBCs were split into 
three sets of 11 donor RBCs for evaluation. All panels were 
DTT-treated at the same time and then separated into their 
designated testing sets. The DTT treatment was verified at 
time of treatment using an antigen known to be destroyed by 
DTT (Anti-k [Cellano]; Immucor) as the DTT control. Set 1 
was reconstituted to a 3–5 percent solution with pH 7.3 PBS 
(Lonza, Walkersville, MD). Set 2 was reconstituted to a 3–5 
percent solution with pH 7.3 PBS. Set 3 was reconstituted in 
an RBC preservative (Alsever’s solution; Sigma-Aldrich).
Antigen Typing
Set 1 DTT-treated RBCs were tested with antisera by 
manual tube method. A double-dose RBC, single-dose RBC, 
and RBC known negative for the selected antigen were tested 
and the results documented daily. Antisera testing included 
all common, clinically significant antigens known not to be 
affected by DTT treatment (Anti-D Series 4, Anti-C, Anti-c, 
Anti-E, Anti-e, Anti-Jka; Anti-Fya, Anti-Fyb; Immucor). 
Anti-M and Anti-S were generated via in-house protocols from 
human sources at a community blood center. Antigen testing 
was performed following package inserts for commercial 
antisera. For human-source Anti-S and Anti-M, indirect 
antihuman globulin testing was performed using polyethylene 
glycol to detect the antigens. Quality control for the human-
source antisera and commercial antisera were documented on 
the day of testing. The antigen typing was completed daily on 
Set 1 for 14 days for comparison of antigen stability over time. 
The antigen testing was performed by the same technologist 
each day. The panel was stored in Alsever’s solution at 2°C to 
8°C. The panel was manually washed each day with normal 
saline and then resuspended in pH 7.3 PBS prior to antigen 
testing. Antigen testing was not viewed by a second reviewer; 
however, reactions were read and graded according to method 
1–9 in the AABB Technical Manual.4
Set 2 DTT-treated RBCs were stored in pH 7.3 PBS. Set 3 
DTT-treated RBCs were stored in Alsever’s solution. Set 2 and 
Set 3 were visually assessed daily for 14 days for observation 
of any indication of hemolysis. All three sets were refrigerated 
(2°C to 8°C) between testing.
Results
Reactivity with double-dose RBCs of Set 1 is shown 
in Table 1. To demonstrate the stability of the DTT-treated 
double-dose RBCs, the number of antigens that maintained 
the baseline grade (day 0) at day 14 was compared with grades 
at day 1 (Table 2). These data show that there were no antigens 
with a grade difference greater than 2. This finding was not 
significant (p = 1.0). Reactivity with single-dose RBCs of Set 
1 is shown in Table 3. To demonstrate the stability of the DTT-
treated RBCs when only a single dose of the antigen being 
tested was present, the number of antigens that maintained 
the baseline grade (day 0) at day 14 was compared with grades 
at day 1 (Table 4). These data show that there were no antigens 
with a grade difference greater than 2. This finding was not 
significant (p = 1.0).
There were 130 data points for the 10 antigens for each of 
the two levels of antigen expression. To understand if there is 
a difference between single-dose and double-dose expression, 
the breakdown by grade difference compared with baseline is 
shown in Table 5. Although there was no statistical difference 
in the number of samples with a two-point grade differential 
from baseline, the difference for those with a one-grade 
differential was significant (p < 0.05). This observation is also 
reflected in the overall number of grades that are not equal to 
or greater than the baseline.
Rh blood group antigens displayed consistently stronger 
reactivity (3+ to 4+) throughout the study (14 days) in 
comparison with the other RBC antigens, which displayed 
more variation and weaker strengths of 2+ to 4+ (averaging 2+ 
to 3+). Nevertheless, following DTT treatment over 14 days, all 
antigen reactivity remained at a strength of 2+ or greater, with 
both amounts of antigen expression on the panel of RBCs. This 
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finding suggests that the antigens tested are stable following 
DTT treatment when stored in Alsever’s solution for up to 14 
days. Further studies with a larger sample volume to include 
additional sources of antisera and RBCs of varied phenotypes 
and varied testing platforms will be needed to confirm this 
observation.  
Aliquot Sets 2 and 3 were only monitored for hemolysis 
notation. On day 3, Set 2, which contained cells stored in 
PBS, displayed slight hemolysis (Fig. 1). By day 8, complete 
Table 1. Set 1: Reactivity with DTT-treated double-dose RBCs
Antisera
Day of testing
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
D 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+
C 3+ 3+ 3+ 3+ 3+ 4+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+
c 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+
E 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+ 4+ 4+
e 3+ 4+ 4+ 4+ 4+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 2+ 3+
Fya 4+ 3+ 3+ 3+ 2+ 3+ 2+ 2+ 3+ 2+ 3+ 2+ 3+ 3+ 3+
Fyb 3+ 3+ 2+ 3+ 2+ 3+ 2+ 2+ 3+ 2+ 2+ 2+ 3+ 2+ 2+
Jka 4+ 3+ 3+ 3+ 3+ 3+ 2+ 2+ 2+ 3+ 3+ 3+ 3+ 2+ 2+
M 4+ 4+ 3+ 4+ 4+ 3+ 3+ 3+ 3+ 4+ 3+ 3+ 3+ 4+ 3+
S 3+ 3+ 2+ 2+ 2+ 2+ 2+ 2+ 3+ 2+ 3+ 3+ 3+ 2+ 2+
DTT = dithiothreitol; RBCs = red blood cells.
Table 2. Set 1: Day 1 and day 14 reactivity comparison with 
baseline (day 0) on DTT-treated double-dose RBCs
Number of antigens
Reactivity Day 1 Day 14 p
≥ baseline 8/10 5/10 0.35 (ns)
± 1 grade 10/10 9/10 1.0 (ns)
± 2 grades 10/10 10/10 1.0 (ns)
DTT = dithiothreitol; RBCs = red blood cells; ns = not significant.
Table 3. Set 1: Reactivity with DTT-treated single-dose RBCs
Antisera
Day of testing
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
D 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+ 4+ 4+ 4+
C 3+ 3+ 3+ 2+ 3+ 3+ 3+ 3+ 2+ 3+ 3+ 3+ 3+ 3+ 3+
c 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+
E 4+ 4+ 4+ 4+ 3+ 4+ 3+ 3+ 3+ 3+ 3+ 3+ 4+ 3+ 4+
e 4+ 4+ 3+ 4+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 2+ 3+
Fya 3+ 2+ 3+ 2+ 2+ 3+ 2+ 2+ 2+ 2+ 3+ 2+ 2+ 2+ 3+
Fyb 3+ 3+ 2+ 3+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 2+
Jka 3+ 2+ 2+ 3+ 3+ 3+ 2+ 2+ 2+ 2+ 2+ 3+ 3+ 3+ 2+
M 4+ 3+ 3+ 3+ 4+ 2+ 3+ 3+ 3+ 3+ 2+ 2+ 3+ 3+ 2+
S 3+ 2+ 2+ 2+ 2+ 2+ 2+ 2+ 3+ 2+ 2+ 3+ 2+ 2+ 2+
DTT = dithiothreitol; RBCs = red blood cells.
Table 4. Set 1: Day 1 and day 14 reactivity comparison with 
baseline (day 0) on DTT-treated single-dose RBCs
Number of antigens
Reactivity Day 1 Day 14 p
≥ baseline 6/10 5/10 1.0 (ns)
± 1 grade 10/10 9/10 1.0 (ns)
± 2 grades 10/10 10/10 1.0 (ns)
DTT = dithiothreitol; RBCs = red blood cells; ns = not significant.






1 grade  
< baseline
2 grades  
< baseline
≥ 3 grades  
< baseline
Double-dose 130 72 48 10 0
Single-dose 130 51* 74* 5 0
Total 260 123 122 15 0
*p < 0.05 for comparison with double-dose reactivity.
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hemolysis was seen in Set 2 (Fig. 2). Aliquots of Set 3, which 
contained cells stored in Alsever’s solution, showed no 
hemolysis throughout the 14-day investigation. 
Discussion
There is a significant need to establish the antigen 
stability of DTT-treated RBCs to support laboratory efficiency. 
Antibody workups on patients taking DARA are becoming 
more common in IRLs and are time-consuming procedures 
requiring advanced technical skills. Some transfusion services 
are also considering the idea of bringing this work in-house. 
This study shows the ability to DTT-treat panel RBCs and to 
store them in Alsever’s solution for up to 14 days; this would 
save institutions tech time, resources, and money.
Fung et al.4 document the use of PBS with an 8.0 pH. In our 
study, the use of PBS with a pH of 7.3 was used. This decision 
was made based on the notation on the package insert stating 
that PBS pH of 6.5–7.5 should be used for antigen typing.
Commercial monoclonal and polyclonal antisera, as 
well as human-source antibodies, were used in this study. A 
variation in the source of antisera, however, did not suggest a 
significant difference in reaction strengths over time. Anti-Jkb 
was not used because it was unavailable at the start of testing. 
All antigen reactivity remained 2+ or greater following DTT 
treatment for the remaining 14 days when stored in Alsever’s 
solution.
Both single-dose and double-dose antigens displayed no 
significant change in stability over the 14-day time frame. This 
study suggests the ability to DTT-treat a large volume of RBCs 
and store them for later use. This practice would be beneficial 
to laboratories that receive samples from patients on DARA 
while also using the RBCs to resolve other complex antibody 
cases. This practice is not limited to the patient population 
being treated with DARA. When using DTT-treated RBCs, 
one must remember that Kell and Lutheran blood group 
antigens are destroyed5,6; a policy would be needed by each 
facility defining how to include and/or exclude their respective 
antibodies.
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Fig. 1 Set 2 (right), Set 3 (left): On day 3, Set 2 (which contained 
cells stored in phosphate-buffered saline) displayed slight hemolysis.
Fig. 2 Set 2 (right) Set 3 (left): By day 8, complete hemolysis was 
seen in Set 2.
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This study was conducted monitoring antigen strength 
and hemolysis. It was not performed on multiple occasions. 
One set of panel cells was monitored for the 14-day time frame. 
Strengths with other donors may vary.
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